LABORATORIOS FARMACEUTICOS ROVI, S.A. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 78.8 EUR | -1.01% |
|
-0.82% | +30.90% |
| Apr. 02 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
| Mar. 12 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
Presenter SpeechJavier López-Belmonte Encina (Executives)Good afternoon, and welcome, everybod...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows:
- pharmaceutical products manufactured under contract (49%);
- prescription pharmaceuticals (45%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.;
- diagnostic products (6%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals.
Net sales break down by source of revenue between sales of products (50.6%), sales of services (49.3%) and sales of licenses (0.1%).
Net sales are distributed geographically as follows: Spain (33%), European Union (17.3%), OECD countries (45.9%) and other (3.8%).
Sector
Pharmaceuticals
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
79.6
EUR
Average target price
79.18
EUR
Spread / Average Target
-0.53%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +30.90% | 4.41B | |
| +25.61% | 660B | |
| +23.33% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| +13.06% | 219B | |
| -9.28% | 196B | |
| +7.01% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- ROVI Stock
- News Laboratorios Farmaceuticos Rovi, S.A.
- Transcript : Laboratorios Farmaceuticos Rovi, S.A., H1 2022 Earnings Call, Jul 27, 2022
